Weekly Companion Animal News: December 22, 2025

Royal Canin-supported pet obesity clinic in Liverpool celebrates 20th anniversary

The world’s first dedicated weight loss clinic for pets – the University of Liverpool Royal Canin Obesity Care Clinic – has supported 540 dogs and 196 cats and overseen the collective shedding of 2.7 tonnes (3 US tons) since its founding in 2005. Clients are not charged for investigations performed that are related to the Obesity Care Clinic, for follow-up weight check appointments or for the first bag of food.

adoro Pet Insurance launches in 28 states

Founded by Gavin Friedman and Tricia Plouf, adoro Pet Insurance Services is currently live in AL, AR, AZ, CO, CT, DC, DE, GA, ID, IL, IN, MD, MI, MN, MO, NE, NV, NH, NM, NC, OH, OR, PA, TX, TN, UT, VA and WI, with more coming soon. adoro is majority-owned by Griffin Highline Capital LLC and Badger Equity. Its underwriting capacity will be provided by Crum & Forster.

NYC’s Animal Medical Center completes $125 million construction project

Schwarzman Animal Medical Center has completed its $125 million construction project, renovating the 1960s building and adding a nine-story tower beside and above it. The center has five new operating rooms, an enlarged emergency room and facilities for specialties including cardiology, neurology, ophthalmology, radiology and oncology.

CurifyLabs launches compounding tool for veterinary medications

Helsinki, Finland-based CurifyLabs announced Curablend Vet, a veterinary excipient system that enables 3D-printed, palatable and personalized medicines for pets. The company’s compounding tool for human medications is widely used in hospitals and pharmacies in the U.S. and Europe, according to the firm.

Jaguar announces extension of FDA conditional approval for Canalevia-CA1

Jaguar Health announced that the FDA granted renewal through Dec. 21, 2026, of the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets), a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. A confirmatory effectiveness trial is expected to conclude in February 2026, according to the company. Canalevia-CA1 initially received conditional approval from the FDA for the treatment of CID in dogs in December 2021.

Europe adopts ‘positive opinion’ for chewable NSAID for dogs

The European Medicines Agency adopted a positive opinion for Firocoxib CP-Pharma chewable tablet for post-operative pain and inflammation associated with soft-tissue, orthopedic and dental surgery in dogs. The positive opinion means the medication from Germany-based CP-Pharma will next face full European Commission review and potential marketing authorization.

Cambridge, Wellcome Sanger Institute to explore biomarkers in canine OA

The Queen’s Veterinary School Hospital at the University of Cambridge is joining forces with the Wellcome Sanger Institute in Hinxton, UK, to examine the genetic changes that occur in canine osteosarcoma tumors with the aim of identifying biomarkers that can lead to earlier diagnoses and more accurate prognoses and lead to development of new treatment options.

U of Ilinois vet makes case for spaying guinea pigs

Reproductive disease arises spontaneously in guinea pigs more commonly than many owners realize, says Dr. Mariana Sosa Higareda, a veterinarian at the University of Illinois Veterinary Teaching Hospital who specializes in zoological medicine. An elective spay in healthy guinea pigs reduces the risk of developing reproductive disease, provides effective contraception and is technically easier to perform and less likely to involve complications, she says.